Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years (APARR)

NCT06646497 PHASE2 NOT_YET_RECRUITING

Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor. Hematopoietic stem cell transplantation (HSCT) is the unic valid therapeutic option but results have always been disappointing in patients aged 40 years or older. The first cause of death after HSCT in those refractory/relapse SAA patients is still graft versus host disease (GvHD). Recently, new strategies to prevent GvHD, including T-cell replete grafts with administration of post-transplantation cyclophosphamide (PTCy), have revolutionized the field, notably in haplo-identical donor setting. Using marrow as source of stem cells and a PTCy strategy not only in haplo-identical donor setting but also in case of an available matched sibling or unrelated donor might prevent drastically GvHD and eventually be practice changing. Evaluating this new strategy is the main objectives of "APARR".

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	52
Start date	Fri Nov 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Aplastic Anemia

Interventions

• Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow

Countries

France